| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-190 | |
| Phytochemical name or plant extracts | Carrichtera annua extract | |
| PMID | 33339242 | |
| Literature evidence | Therefore, C. annua herb seems to be a promising candidate to further advance anticancer research. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Crude and phenolics extract | |
| Source of phytochemicals or plant Extracts | Carrichtera annua | |
| Geographical availability | Algeria, Baleares, Canary Is., Cyprus, Egypt, Greece, Iran, Iraq, Kriti, Kuwait, Lebanon-Syria, Libya, Morocco, Palestine, Portugal, Sardegna, Saudi Arabia, Sicilia, Sinai, Tunisia, Western Sahara | |
| Plant parts | Aerial parts | |
| Other cancers | Breast cancer, Lung cancer, Liver cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 13.04 µg/mL against MCF-7 | |
| Potency | Flavonoid fraction of C. annua was more active than the crude extract. It demonstrated selective cytotoxicity against the MCF-7 and HepG2 cells (IC50 = 13.04 and 19.3 µg/mL respectively), induced cell cycle arrest at pre-G1 and G2/M-phases and displayed apoptotic effect. | |
| Cell line/ mice model | MCF-7, HepG2 | |
| Additional information | Moreover, the extract exhibited promising reduction ability (1.17 mMol Fe+2/g) in comparison to the positive control (ascorbic acid with 2.75 ± 0.91) and it displayed some definite radical scavenging effect on DPPH (IC50 values of 211.9 ± 3.7 µg/mL). Our results put forward that C. annua is a promising candidate to counteract chemotherapy side effects and the observed activity could be attributed to the synergism between its phytochemicals. | |
| PubChem ID | NA | |
| Additional PMIDs | 34064100 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:280826-1 | |
| Safety | NA |